iRadimed (NASDAQ:IRMD) Reaches New 52-Week High – Here’s What Happened

iRadimed Corporation (NASDAQ:IRMD) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $100.01 and last traded at $99.2150, with a volume of 95385 shares. The stock had previously closed at $95.50.

Analyst Ratings Changes

IRMD has been the topic of several analyst reports. Zacks Research upgraded iRadimed to a “hold” rating in a report on Tuesday, November 4th. Lake Street Capital reaffirmed a “buy” rating and issued a $100.00 price objective on shares of iRadimed in a research note on Monday, November 3rd. Roth Capital set a $90.00 price objective on shares of iRadimed in a research report on Friday, October 31st. Wall Street Zen downgraded shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.33.

iRadimed Trading Up 0.3%

The firm’s 50-day moving average price is $91.93 and its 200 day moving average price is $76.42. The company has a market cap of $1.25 billion, a price-to-earnings ratio of 59.60 and a beta of 1.09.

iRadimed (NASDAQ:IRMD) last released its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The company had revenue of $21.20 million for the quarter, compared to the consensus estimate of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. Analysts forecast that iRadimed Corporation will post 1.66 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The company also recently announced a special dividend, which was paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th were given a $0.50 dividend. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed’s payout ratio is presently 41.21%.

Insider Buying and Selling

In other news, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $97.66, for a total transaction of $488,300.00. Following the transaction, the chief executive officer directly owned 2,282,500 shares of the company’s stock, valued at $222,908,950. This represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO John Glenn sold 15,000 shares of the stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $97.29, for a total value of $1,459,350.00. Following the completion of the transaction, the chief financial officer owned 7,362 shares in the company, valued at approximately $716,248.98. This represents a 67.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 60,000 shares of company stock worth $5,326,900. 36.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Johnson Investment Counsel Inc. raised its stake in shares of iRadimed by 0.7% in the third quarter. Johnson Investment Counsel Inc. now owns 25,842 shares of the medical equipment provider’s stock valued at $1,839,000 after buying an additional 187 shares during the period. Summit Global Investments grew its stake in shares of iRadimed by 2.7% during the 3rd quarter. Summit Global Investments now owns 7,139 shares of the medical equipment provider’s stock worth $508,000 after acquiring an additional 188 shares during the period. CWM LLC increased its holdings in iRadimed by 62.2% in the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 211 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in iRadimed by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after acquiring an additional 234 shares during the last quarter. Finally, Comerica Bank raised its stake in iRadimed by 21.4% in the 1st quarter. Comerica Bank now owns 2,288 shares of the medical equipment provider’s stock valued at $120,000 after acquiring an additional 404 shares during the period. 92.34% of the stock is owned by institutional investors.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.